ABSTRACT Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip, vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical femur fractures (AFFs) emerged as potential side effects of BPs and other treatments. These fractures have unusual radiologic features and occur with little trauma. Public concern has led to a .50% decrease in BP usage. AFFs are rare: for each AFF, .1200 fractures, including 135 hip fractures, are prevented. Case definition criteria were updated by the American Society of Bone and Mineral Research in 2014. Many epidemiologic studies have been reported, and although methodologically challenging, generally support a BP-AFF association. However, the magnitude of the association between BPs and AFFs is uncertain: estimates of relative risk for AFFs among BP users vs nonusers range from 1 to 65 with a meta-analysis estimate of 1.7. Although mechanistic studies have proposed several hypotheses explaining how BPs might decrease bone strength, AFF pathogenesis remains uncertain and cannot explain the paradox of efficacy of reduction of common fractures while increasing risk for rare fractures at one site. There are several consistent risk factors, including Asian race (in North America), femoral bowing, and glucocorticoid use, whereas others remain unclear. Consensus is emerging about strategies to prevent AFFs in BP users (including drug holidays after 5 years' use in some patients). In conclusion, AFFs can be devastating, but even under the most pessimistic assumptions, the benefit/ risk ratio is highly positive for BPs, particularly during 3 to 5 years of use. As understanding of AFFs increases, it is becoming increasingly possible to maximize BP benefits while minimizing AFF risk. (Endocrine Reviews 40: 333 -368, 2019) S ince the early s, bisphosphonates (BPs) have been the mainstay in the treatment of osteoporosis. This class of drugs has been shown in randomized controlled trials (RCTs) to prevent osteoporotic fractures by as much as % to % () in women and men with osteoporosis ( Fig. ) . The success of this approach rests on the strengthening of osteoporotic bone that occurs when a reduction in bone remodeling induces an increase in bone mineral density (BMD) and improvements in bone microstructure ().
S
ince the early s, bisphosphonates (BPs) have been the mainstay in the treatment of osteoporosis. This class of drugs has been shown in randomized controlled trials (RCTs) to prevent osteoporotic fractures by as much as % to % () in women and men with osteoporosis (Fig. ) . The success of this approach rests on the strengthening of osteoporotic bone that occurs when a reduction in bone remodeling induces an increase in bone mineral density (BMD) and improvements in bone microstructure ().
Case reports of unusual fragility fractures in the subtrochanteric and femoral shaft (ST/FS) regions in patients treated with BPs were first reported in  to  (, ). A large number of case reports and epidemiologic studies concerning these rare fractures and focusing on their relationship to BPs have been published starting in  (, ). More recently, such fractures have also been observed in RCTs of the biological antiresorptive agent denosumab (-) and with other osteoporosis drugs in development ().
Although subtrochanteric and midshaft fractures are well known in orthopedic surgery, these unusual femur fractures have been noted for having a specific morphologic pattern. Because of this unusual morphology, they have been termed atypical femur fractures (AFFs). Studies from the United States and Singapore (, ) described the unique radiologic features of these fractures, including a transverse morphology, a thickened cortex, and the fact that these fractures occurred either spontaneously or with minimal trauma. The fracture site and their frequent bilateral occurrence raised concerns about BP safety, although the pathophysiology was uncertain. These reports were also noteworthy because they reinforced concerns that bone quality and strength could be negatively affected by accumulation of microdamage if bone remodeling is kept low for a long period of time ().
As more formal epidemiologic studies became available (-), the American Society of Bone and Mineral Research (ASBMR) released a first position paper on AFFs in  () and updated it in  (). Additionally, the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the International Osteoporosis Foundation released a position statement (). A widely publicized Food and Drug Administration hearing on the safety of BPs was held in , creating concerns among patients and physicians about treating osteoporosis with BPs ().
Despite these concerns, AFFs are extremely rare, whereas the hip, vertebral, and other osteoporotic fractures that can effectively be prevented by treatment are much more common. A comparison of the benefits vs risks for BP therapy was recently published (). The results, shown in Table , indicate that the benefits for fracture reduction for short-term therapy for  to  years far outweigh any risks of AFFs. Under the most likely set of assumptions about AFF risk [relative risk of . for any BP use ()], upon treating , osteoporotic women for  years,  fractures, including  hip fractures, would be prevented while causing only . AFFs ( Table ) . Stated another way, for one AFF associated with  years of BP treatment,  fractures (including about  hip and  vertebral fractures) would be prevented (Fig. ) . Thus, the benefits of treatment far outweigh any AFF risks. Despite the overwhelming positive benefit/risk ratio, recent analyses of national trends in osteoporosis medication use in the United States reflect these concerns and document a % decline in BP use from  to  () (Fig. ) , with reports about BP safety (particularly AFFs) as the main reason for this decline. In Europe, BP use peaked in  to , with a subsequent decline (). The public health message has been a challenging one, owing in large part to confusion about the clinical interpretation of relative vs absolute risks. Casual readers of the literature may conclude that prescribing BPs to patients increases their AFF risk by a factor of  to , whereas decreasing their risk of osteoporotic fractures by~% implies that the risks overwhelm benefits. However, osteoporotic fractures are very common, whereas AFFs are extremely rare. If calculated appropriately using absolute risks, the message is entirely different with a very large BP-driven reduction in the total fracture burden ().
The ASBMR has issued a Call to Action () to address this problem and reinforce the appropriate use of BPs and other osteoporosis medications. 
ESSENTIAL POINTS
· Atypical femur fractures (AFFs) are extremely rare and although associated with bisphosphonate (BP) use (particularly long-term use), they are much rarer than the common hip and vertebral fractures that can be effectively prevented by BPs · The benefit/AFF risk ratio for 3 to 5 years of BP use in osteoporotic women is overwhelmingly positive: for each AFF caused by BPs,~1200 fractures, including 135 hip fractures, would be prevented · Certain groups of patients are at higher AFF risk, including patients on glucocorticoids and patients of Asian ancestry (in North America): these patients should be more closely monitored, particularly after 3 to 5 years of BP use · Patients on long-term BPs should be queried about thigh pain and, if present, imaging to assess cortical thickening or stress fractures should be conducted · In patients with signs of incomplete AFFs, BPs should be discontinued and, in patients with a visible incomplete AFF fracture line, prophylactic surgery can be considered · There is some evidence that temporary drug holidays (up to 3 to 5 years) for patients at lower levels of risk for osteoporotic fracture could reduce AFF risk without loss of substantial benefits from BP therapy during the drug holiday
Despite the impact of AFF concerns on antiosteoporosis medications use, there remains significant uncertainty and controversy about the magnitude of the relationship between the use of osteoporosis therapies and duration of therapy to the risk of AFFs and about the pathophysiology of AFFs. This review discusses the current evidence regarding their epidemiology and pathogenesis, clinical implications, and recommendations, and it identifies areas where future research is needed.
Note that this review does not discuss other side effects of BPs such as gastric irritation with oral BPs, acute phase reaction with IV BPs, or osteonecrosis of the jaw (ONJ). ONJ is extremely rare but is a concern for some patients. The reader is referred to a  review of ONJ ().
Definition of AFFs
The ASBMR definition AFFs have distinctive characteristics that distinguish them from more commonly encountered hip or femur fractures. In , the ASBMR established a task force and published their criteria to define AFFs (). The criteria were selected to mirror the characteristics noted in early case reports and to offer as much discrimination as possible between femur fractures occurring in BP-naive and BP-treated subjects. The ASBMR AFF criteria were revised in  as more information about the epidemiology and morphology of AFFs became available (, ). The revised definition is shown in Table  . The definition requires that at least four of the five major features are present to meet the case definition. An example of a complete AFF, illustrating the ASBMR criteria, is shown in Fig.  .
Two features that have been associated with AFFs since the early case reports are a transverse line through the lateral cortex and focal cortical thickness of the lateral cortex at the fracture line. However, note that since only four of the five major criteria are required in the  criteria, it is possible that a fracture that is, for example, not transverse in the lateral cortex or that is not associated with focal cortical thickening would meet the ASBMR definition for AFFs.
It is often helpful to have both presurgery and postsurgery radiographs to evaluate these features. Although the criteria for the ASBMR definition are clear, in practice, there can be ambiguities in the definition of the individual features or other aspects of the definition such as the location of the fracture ().
Epidemiology of AFFs

Epidemiology overview
Since the first case reports and case series were published in  to , a large number of epidemiologic studies have been performed with a primary goal of gaining insight into the relationships between BP and other osteoporotic medication use and AFFs or ST/FS fractures. An overriding challenge of this research is that people with low BMD and/or high fracture risk are both more likely to take BPs and are more likely to have osteoporotic fractures including AFFs. Parsing out the impact of the underlying risk from the effect of the medications is very challenging due to lack of adjustment for fracture risk in most studies. Additionally, another challenge to epidemiologic studies is that the incidence of AFFs is extremely low and there is limited availability of radiographs. Table  summarizes the key epidemiologic studies that are discussed in more detail in the sections below. A more comprehensive list of studies is included in the ASBMR AFF task force reports (, ).
Fracture endpoints used in epidemiologic studies
For defining the endpoint of interest in epidemiological studies, three general methods have been used depending on the source of patients, data in the study, and the study design. The choice has important implications for the interpretation of the studies. The three approaches are described below (see Table  and Fig. ) . AFFs evaluated from radiographs. For studies that have access to fracture radiographs, AFFs can be evaluated from the radiographs. Prior to , the criteria used to evaluate the radiographs varied. With the introduction of the first set of ASBMR criteria in , most studies have used these criteria, resulting in more standardization of the definition. More recently, since the introduction of the revised criteria in , studies have begun to use this revision. For ST/FS fractures that have been defined by radiographic adjudication review, we will use the abbreviation ST/FS-adj.
Use of International Classification of Disease codes. Studies using administrative databases where fracture radiographs are not available, such as national databases or Medicare, have used as endpoints the broader category of ST/FS fractures based on International Classification of Disease (ICD) codes for ST/FS fractures. For ICD-, these codes are S and S. In this review, we use the abbreviation ST/FS-icd to refer to this definition. Importantly, most fractures in this very broad category do not meet AFF criteria. One study reviewed . radiographs within these two ICD classifications and found only % of the fractures with the two relevant ICD codes met AFF criteria (Figs.  and ) (), and another study showed a similarly low percentage (% to %) (). A study restricted to BP users reported a somewhat higher proportion of ICDcoded ST/FS fractures that met AFF criteria (%), but upon radiographic review, most were either periprosthetic or were reclassified as proximal femur or distal femur fractures (). However, it is clear that at least % and as much as % of fractures within the two relevant ICD codes do not meet AFF criteria. Clearly AFF and ST/FS-icd endpoints represent different clinical outcomes, making it necessary to distinguish studies with each endpoint from one another.
Use of fracture radiology reports. In one prospective cohort study and three randomized trials, radiology reports that were collected during the studies were later used to identify a set of ST/FS fractures based on the narratives in the reports. Fractures defined by this method are abbreviated as ST/FS-rad. These reports may be more specific than ICD codes only because they can more likely exclude periprosthetic and pathologic fractures and classic hip fractures that have been miscoded, which account for most ST/FS-icd fractures that do not meet AFF criteria ().
Study designs in epidemiological studies of AFFs and ST/FS
Another important difference among epidemiologic studies is the study design and, relatedly, the choice of controls to whom the fracture cases are compared (see Table  ).
Cohort studies. These are studies that have examined a defined population and a specific time frame with a goal of identifying all relevant fracture cases within that population. This study design allows for the possibility of estimating the true incidence rate and, hence, the absolute magnitude of increase in risk attributable to BPs. Several of these are national or regional studies that have identified cases during a multiyear period. Only three of these studies have had radiographs available to define AFFs whereas others have relied on ST/FS-icd or ST/FS-rad for the fracture definition.
Case-control studies. These are studies in which a set of fracture cases is selected and compared with a set of controls. In most case-control studies, radiographs are available to define AFF cases more precisely. Most case-control studies have chosen non-AFF ST/FS fractures as controls, which places important limits on the interpretation of the study. Case-control studies can provide an estimate of the increase in risk of AFFs (in most cases compared with other ST/FS fractures) but cannot estimate incidence or the absolute increase in risk associated with BP use. Two case-control studies are nested within population cohorts providing some theoretical advantages compared with the more common clinic-or hospital-based case-control studies.
Randomized placebo group as a control group, eliminating many of the confounding problems inherent in observational cohort and case-control studies. Two large trials of BPs performed post hoc analyses of ST/FS-rad fractures comparing the group randomized to BP to those randomized to placebo.
In the discussion of epidemiology below, this review focuses on key studies that have used each of the three study designs.
Cohort studies. Cohort studies identify subjects in a defined population and can classify their exposure characteristics (e.g., use of BPs) prior to the fracture events.
Cohort studies based on x-ray review for AFFs: Three studies performed in population-based cohorts were able to obtain radiographs for potential AFFs, review individual radiographs, and studied BP exposures for the entire populations. These include studies in Kaiser Permanente Southern California (KPSC), Kaiser Permanente Northwest (including Oregon and Hawaii) Region (KPNW), and a national study in Sweden.
A study in the KPSC health maintenance organization (HMO) established a cohort of . million people  years of age or older who were members between  and . From this cohort, they reviewed radiographs for all femur fractures with possible AFF indicators occurring within this HMO population during  to . AFF status was evaluated during the  years by three reviewers (). The reviews (performed before ASBMR criteria were available) defined AFF status based on three criteria: location in ST/FS region, transverse fracture pattern, and lateral cortical thickening. Age, sex, BP use, and duration (time of first use to time of last use) were established from patient records. Pharmacy records were available from  and beyond. During the  years, there were , femoral fractures, and after the radiographic review,  cases with AFFs were identified. Twenty-eight (%) patients had bilateral AFFs during the study period. Sixty-nine percent of cases had medical record evidence of prodromal pain. Ninety percent of cases had taken a BP, and % had no history of BP. Among patients with no history of BP use, the rate was . per , person-years (py). Among those with a history of BP use, the AFF rate was higher and increased significantly with longer duration (see Impact of BP duration on AFFs below). The study adjusted for age only (with little difference in results), but importantly it could not adjust for osteoporosis severity or other key covariates.
The KPNW study included women . years of age and men . years of age who were KPNW members between  and . An initial analysis published in  () used the  ASBMR criteria () and identified  AFFs. A reanalysis of these data published in  used the  ASBMR criteria () and was able to compare the  to the  ASBMR AFF criteria. Applying the  ASBMR criteria, the number of AFFs decreased from  to . Among those with Kaiser Permanente membership for . year, there were a total of  ST/FS-adj fractures, of which  were AFFs and  were non-AFF ST/FS.
To study the relationship of BP use to AFFs, they performed a case-control analysis comparing prior BP use in those with AFFs (n = ) to those with ST/FSadj without atypical features (n = ). The unadjusted OR for any BP use and AFFs calculated from the results in the publication is . (% CI, . to .). This study did not provide information about BP duration.
A unique feature of this study was the calculation of yearly incidence rates from  to  for AFFs, ST/FS-adj, and hip (femoral neck or intertrochanteric) fractures. These are shown in Fig.  . Between  and , the rate of ST/FS-adj (all ST/FS fractures, AFFs plus non-AFFs) was either constant or declined slightly. In  to , the rate was~ to  per , py whereas in  to , it was~ to  per , py. The rate of AFFs increased from  to  per , py in  to  to~ to  per , py in  to  and then declined slightly. Although the numbers are small and therefore variable, they suggest that the number of fractures in the ST/FS region are not increasing over time, although the proportion of them that are AFFs may be increasing slightly from  to . For comparison, the rates of hip fracture were~-fold the rate of AFF (, ).
Two analyses of AFFs at a national level in Sweden have been published, with the first using data in women from  and the second including the same  data but adding women and men from  and  (, ). For the latter analyses, all radiographs (n = ) were requested for fractures with ICD- codes for subtrochanteric or femoral shaft fractures. Pharmacy records were available starting in July , so historical duration for BP use is truncated. This means that there is no ability to distinguish moderate term use (e.g.,  years) from longer-term use. A total of  radiographs were obtained and reviewed for AFFs using  ASBMR criteria. After review,  met AFF criteria and  met criteria for ST/FS-adj but were not AFFs. Of the  cases in women,  (%) occurred in women with no history of BP use whereas  (%) occurred in women with a history of BP use. The incidence was . per , py in nonusers of BP vs  per , py in women with any previous BP use. For calculating the increase in risk associated with BP use, as was done in the KPNW study, there was a case-control study nested within this cohort study that compared BP use in those with AFFs to those with non-AFF ST/FS-adj. The age-adjusted OR was  (% CI,  to ).
It is interesting to compare the KPNW study and the Swedish case-control analyses with respect to the relationship of BP use to AFFs. The two studies are virtually identical in design: they are both large population-based studies, used the  ASBMR criteria to evaluate radiographs, and compared AFF cases to ST/FS-adj controls without AFF features. However, the results from these two studies are remarkably discrepant: the LeBlanc study from KPNW showed an OR-related BP use to AFFs of . vs  for the Swedish study. This discrepancy is representative of the uncertainties among the case-control studies and is difficult to explain, but it might be due to differences in criteria for AFF evaluation, length of treatment, populations, or subtle study design differences.
Cohort studies based on ICD diagnostic codes: A number of large cohort studies have been performed defining ST/FS fractures as the outcome from administrative databases using the two ICD codes for these two regions (ST/FS-icd; ICD-, S and S). Unlike the case-control studies discussed above and in the section below, these used nonfracture cases as the comparator group.
A Danish national analysis in  found a % increased risk of ST/FS-icd fractures for those with any BP use [hazard ratio (HR), .; % CI, . to .] in a cohort analysis specific to patients with prior major osteoporotic fractures (). Because BPs are prescribed for high fracture risk, those taking BPs were likely at higher risk for all types of fractures (including AFFs). Therefore, the increased risk seen in this study combines both the higher risk of ST/FS fractures among patients who are prescribed osteoporosis treatment as well as any increase in AFFs with treatment. Restricting the analysis to patients with prior fracture was done with the intention of providing some degree of comparability in fracture risk between To satisfy the case definition of AFF, the fracture must be located along the femoral diaphysis from just distal to the lesser trochanter to just proximal to the supracondylar flare.
Additionally, at least four of the five Major Features must be present. None of the Minor Features is required but have sometimes been associated with these features.
Major features a
• The fracture is associated with minimal or no trauma, as in a fall from a standing height or less.
• The fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may become oblique as it progresses medially across the femur.
• Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex.
• The fracture is noncomminuted or minimally comminuted.
• Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site ("beaking" or "flaring").
Minor features
• Generalized increase in cortical thickness of the femoral diaphysis.
• Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh.
• Bilateral incomplete or complete femoral diaphysis fractures.
• Delayed fracture healing.
[ Other cohort studies have used actively treated groups as comparators, either non-BP treatment or low usage BP groups. This comparator group has an important advantage in that all study patients were treated, which implies that they all had some level of osteoporosis and provides a level of adjustment for indicators for treatment. This is a commonly used approach in pharmacoepidemiology, as it ensures that the comparator group also represented subjects with elevated base fracture risk as the indication for treatment. One such study using US claims databases compared BP users to matched patients treated for osteoporosis using raloxifene or calcitonin, weaker antiresorptive drugs used for the same indication. This study found similar rates of ST/FS-icd fractures among BP users ( per , py) vs controls (among non-BP users,  per , py) and concluded that there was no increased overall risk with BP use (). A Canadian study used government health care data in Ontario, Canada, defining ST/FS-icd fractures through ICD codes and compared use for $ years of use to , year and found a significant, but modestly, elevated risk (adjusted OR, .; % CI, . to .) (). However, although fundamentally attractive as a means of addressing allocation bias, active comparator designs rely on the assumption that base risks were not substantially different for the different treatment options, something that is unlikely to be true in osteoporosis where weaker antiosteoporosis medications such as raloxifene may often be given to those with more mild disease.
Several studies have used large databases to compare more highly adherent patients to those with lower adherence. Presumably, these patients would have the same risk for fractures overall, given that they were prescribed an osteoporosis therapy. In one study using Medicare data, , new BP users were tracked in the Medicare claims database from their index prescription (). The study made use of a common pharmacoepidemiologic approach to look for greater effect sizes in people with higher drug exposure. If BPs cause some fractures of the subtrochanteric femur or femoral shaft and prevent some fractures of the hip, then these effects should be more pronounced in highly adherent patients than in those with lower adherence. The study reported that patients with the best adherence showed the highest rate of ST/ FS-icd fractures ( vs  per , py) and the lowest rate of hip fractures ( vs  per , py). Note that even if all of the excess ST/FS cases could be attributed to treatment, it is a much smaller increase than the decrease in hip fractures. The authors concluded that treatment led to an overall fracture risk reduction but recommended monitoring for a possible increased risk of ST/FS fractures. In contrast, a recent Danish cohort of , BP users with twice the follow-up time found that in users who adhered to treatment [with .% medication possession ratio (MPR)], rates of hip fracture declined to a stable  to  per , py, whereas the total ST/FS-icd rate remained stable at  to  per , py. A nested case-control analysis including patients with all degrees of adherence and adjusted for measured differences in comorbidity found no increase in ST/FSicd fracture risk attributable to high adherence (MPR .% vs ,%) (OR, .; % CI, . to .; P = .) and no increased risk with current use over past use or with . dose years of exposure (). Risk reductions for hip fracture paralleled those seen in the primary RCTs.
One prospective cohort study analysis was unique in having BMD and other covariates measured prior to the fractures. This analysis used data from the Study of Osteoporotic Fractures, a prospective cohort study of  nonblack US women . years of age recruited in  to  and followed until . During the study, radiographic reports were collected to prospectively adjudicate fractures and later used in the post hoc analysis to define ST/FS-rad fractures (). Using these reports may be more specific for AFFs compared with ICD codes because non-ST/FS fractures and periprosthetic and pathologic fractures can in all likelihood be more precisely excluded than from ICD codes alone. Radiographic reports from all femur fractures (except femoral neck fractures) were reviewed to identify  ST/FS-rad fractures. An analysis of the relationship of BP use and other predictors was performed using these ST/FS-rad fractures. ST/FS-rad fractures were compared with all others in the cohort without ST/FS fractures in a time-dependent, multivariate analysis. Because this study was a true prospective cohort, it has an advantage that several important covariates collected prospectively, such as BMD but also prior fractures, corticosteroid use, and other important covariates, could be included in a multivariate, time-dependent variable analysis. The fully adjusted relative hazard (RH) for BP use was . (% CI, . to .), suggesting a modest, but statistically significant association of BPs with ST/FS-rad fractures, an effect size similar to that seen in register-based studies that used ICD codes. Providing validation for this fully adjusted approach, after adjustment for factors including BMD and previous fractures, the protective effect for BP use and proximal femur fractures was similar to that seen in randomized trials of BPs (RH, .; % CI, . to .) for femoral neck and (RH, .; % CI, . to .) for intertrochanteric fractures. Unfortunately, the lack of ability to define AFFs by radiographic review is a limitation of this study. Cohort studies-comments and limitations: Cohort studies have a number of advantages compared with case-control studies for addressing the relationship of BPs to AFFs. Cohort studies allow for population-based estimates of incidence and increase in incidence with BP usage and a more precise characterization of BP usage than can be established from retrospective assessment in case-control studies. Another important advantage of these cohort studies is that they have not used fracture controls as have most case-control analyses and studies.
However, despite the clear strength in design, there are some important limitations in many existing studies. Most significantly, except for three studies, cohort studies have relied on ICD coding categories to define the subtrochanteric and femoral shaft fractures (ST/FS-icd) outcome. This very broad category contains a majority of non-AFF cases (e.g., periprosthetic and pathologic fractures, miscoded intertrochanteric fractures, ST-FS fractures that are not AFFs). As discussed above (see Fig.  ), after radiographic review, as many as % of the fractures within the ICD codes S and S would not qualify as AFFs (). However, analyzing the total number of subtrochanteric and femoral shaft fractures-atypical and typical combined-allows for inferences about the potential net harm of treatment of all fractures located in this part of the femur. These studies with ST/FS-icd as an endpoint can therefore provide an estimate of the upper boundary of harm. Another important limitation is that most of these cohort studies from administrative databases, although having extensive information about comorbid conditions and comedication use, lack information on some important covariables, including BMD, body mass index (BMI), and lifestyle factors.
Summary of cohort study results: In the studies that had radiographs available for AFF assessment, the results consistently show that BP users are at higher risk than nonusers. These studies also allow for population-based estimates of AFFs and show them to be very low, much lower than the hip fractures, which can be effectively prevented.
In the studies that did not have access to radiographs but instead used the broad category of ST/FSicd fractures defined based on ICD codes, many but not all show increased risk of ST/FS-icd fractures with BP use. In general, these studies have shown weaker relationships between BP exposure and AFFs than do case-controls studies. However, in the studies that rely on ST/FS-icd fractures, AFFs represent only a small minority of the endpoints (as low as % to %), making these results difficult to interpret.
Case-control studies. Because the incidence of AFFs is so low, the case-control design, which compares AFF cases to controls, is the most practical and powerful design to examine the association of BP use to AFFs. Case-control studies provide OR estimates and are useful for identifying risk factors, including BP use. However, without additional information, this design cannot provide absolute risk or harm estimates. Moreover, the choice of control groups has important implications for the value of the inferences derived from these studies and has been problematic for AFF studies and is discussed below.
The KPNW () and Schilcher et al. () cohort studies discussed above examined the relationship of BP use to AFFs using case-control studies nested within the cohort studies. To summarize the details of these two studies described above, the KPNW study found an OR relating any BP use to AFFs of . (% CI, . to .), and the Swedish study found a much higher OR of  (% CI,  to ).
In terms of the overall OR of BP with AFFs, the other case-control studies show results between the KPNW and Swedish studies. these studies used non-AFF ST/FS-adj fractures as controls.
A Swiss analysis () included  patients with AFFs, of whom  were BP exposed. In this analyses, two control groups were used: ST/FS-adj fractures without atypical features and a nonfracture group. They reported a larger OR (OR, .; % CI, . tp .) when using an ST/FS control group compared with a much lower OR (OR, .; % CI, . to .) when using nonfractured controls. This difference between the results with the two comparator groups supports the potential bias in using a ST/FS-adj fracture control compared with using nonfractured patients as controls.
Case control studies-comments and limitations: An important strength of the case-control studies is that fracture radiographs were available for review so that atypical features could be evaluated. However, an important limitation is that in almost every study, the control/comparator group consists of patients with ST/FS-adj fractures without atypical features. Thus, the results are applicable to consideration of patients with fractures in subtrochanteric or femoral shaft regions only. This means that the ORs reflect the relative probability that a ST/FS fracture, if it occurs, will have AFF characteristics, not the relative risk of sustaining an AFFs per se. This represents a significant limitation of this design. Another important challenge of using ST/FS fracture cases as controls is that any decrease in the risk of non-AFF ST/FS fractures (controls) as a result of BP treatment will artifactually inflate the OR for AFFs because there is a decrease in the denominator in the control group. A further limitation is that these studies had available limited covariates that could be used for controlling for confounding by indication. Most important, BMD values are critical for initial treatment decisions, but none of the casecontrol studies had pretreatment BMD values available as covariates for adjustment.
As case-control studies, all of these studies have the additional limitation that they cannot provide estimates of the absolute increase in risk for AFFs with BP treatment. In general, the case-control studies support a relationship between BPs and AFFs, but the large variation among them in the magnitude of the ORs remains unexplained and requires further exploration in future studies.
Summary of case-control studies: Results from case-control studies are consistent in suggesting an increase in AFFs with BP treatment, but owing to limitations above (e.g., control groups of ST/FS fractures, no estimate of absolute risk increase), they alone are not sufficient to prove such an increase or to quantify the magnitude of increase in absolute risk associated with BP use.
Randomized trials. Randomized, placebocontrolled trials have the potential to provide estimates of the relationship of BP use to AFFs without biases inherent in observational studies. Two randomized trials of BPs in osteoporotic women, one of alendronate and the other of zoledronic acid, had available radiographic reports that were used to evaluate ST/FS-rad fractures within these randomized trials in post hoc analyses. The incidence of ST/FS-rad fractures was compared between randomized groups (BP vs placebo) to assess the relationship of BPs to ST/ FS-rad fractures (). In the Fracture Intervention Trial (FIT) of alendronate,  women were randomized to alendronate or placebo and followed for a mean of . years. Using the radiograph reports, two ST/FS fractures were identified, one each in alendronate and placebo (. per , py) (RH, .; % CI, . to .). In the HORIZON trial of zoledronic acid,  women were randomized for  years. Three ST/FS fractures were found in the zoledronic acid group (. per , py) and two in placebo (. per , py) (RH, .; % CI, . to .). Thus, both of these trials do not show a significant relationship of ST/FS-rad fractures to BP use. However, although the numbers of events are small and CIs are wide, the incidence rates in the placebo groups provide an upper bound on the rate of ST/FS-rad among older, osteoporotic women, with the women most likely to be treated with BPs. A further limitation of these analyses is that the relatively short period of treatment ( to  years) means that conclusions about longer-term treatment cannot be drawn.
Meta-analysis of BP use and AFFs. A metaanalysis of the relationship of BP use and subtrochanteric fractures, femoral shaft fractures, and AFFs was published in  (). After a literature review, the authors identified five case-control and six cohort studies (including the two randomized trials mentioned above) that met quality criteria and provided results relating BP use to AFFs or ST/FS fractures. The results from the random-effects meta-analysis are shown in Fig.  . The overall estimate of risk ratio for any BP use was . (% CI, . to .), corresponding to a % increase in risk for AFFs for any BP use. From the cohort studies, the combined risk ratio was . (% CI, . to .) whereas from the case-control studies the combined risk ratio was . (% CI, . to .), supporting the possible biases inherent in case-control studies with fractures as controls. An important limitation of this metaanalysis is that it pooled a very heterogeneous set of studies in terms of design (case-control, cohort, and RCTs) and fracture endpoint definitions (studies defining AFFs from radiographs vs studies that did not have radiographs and used ICD codes only). The authors reported significant heterogeneity among studies, perhaps explained by the variation in study designs, endpoints, and results.
Since this meta-analysis was published in , there have been several new studies discussed above [e.g., Refs. (, )], and two of the studies were updated (, ). However, these newer results, if added to the  meta-analysis, are unlikely to change the pooled risk ratios substantially.
Impact of BP duration on AFFs
The hypothesis that longer duration of use is more strongly associated with AFFs was proposed in early case reports and case series. The relationship of BP duration to AFFs in studies with radiograph AFF review has been addressed in two cohort studies, and there are also results from some of the smaller casecontrol studies.
In the KPSC cohort study (), rates of AFFs within categories of BP usage were estimated. Among nonusers the rate was . (% CI, . to .) per , py and increased with increasing duration of BP use. For example, for BP use between  and . years, the rate was . (% CI, . to .), and among those with $ years of use, the rate per , py was . (% CI, . to .) [ Fig. (a) ] (). The authors also included age-adjusted rates that were similar, but this study did not control for severity of osteoporosis and it is likely that those with longer use had more severe osteoporosis. Other limitations of this analysis are that the authors defined duration of BP use as the time from the first to the last use, ignoring gaps in between and that the analysis pooling men with very low rates of BP use together with women could bias the estimates of risk by duration.
The  Swedish study () performed a similar analysis to the KPSC study but reported a much steeper relationship of duration to increasing risk of AFFs [ Fig. (b) ]. They calculated relative risk compared with nonusers by duration of BP use. For women, for  to . years of use, the relative risk was ., whereas for duration $ years, the relative risk was .. The high relative risk for short-term use is inconsistent with the lack of relationships seen in RCTs and is unexplained. Again, no adjustments related to osteoporosis severity could be made. Although the Swedish study shows a steeper relationship with BP duration than did the KPSC study, the most important conclusion from these two studies is that these results strongly support that those with longer duration of use have a higher risk of AFFs. Several of the case-control studies, as well as case reports, have also supported that AFFs defined from radiographs are more likely to occur in long-term users.
There are important limitations to observational studies of duration for AFFs, including the fact that longer-term users are more likely to have more severe osteoporosis and that the studies have limited ability to adjust for confounding by treatment indication because the most important variables that go into treatment decisions such as BMD and fracture history were not available. Thus, these studies could not adjust for many important factors related to indication for BP use, and it is likely that the results are biased by the larger number of higher risk patients in the longerterm user groups.
The above results are from studies that have used AFFs defined from radiographs. In contrast with results for radiographically defined AFFs, studies of the relationship of ST/FS-icd fractures to duration have shown varying results. Abrahamsen et al. () showed that increases in ST/FS-icd during  years of alendronate use were similar to those seen with hip fractures, concluding that high risk of both types of fractures with longer-term BP use may be due to the fact that higher risk women used BPs longer as well as the fact that they were older. Alternatively, a Canadian study used government health care data in Ontario, Canada, defining ST/FS-icd fractures through ICD codes (not radiographic evaluation) and compared use for $ years to , year of use and found a slightly elevated risk (adjusted OR, .; % CI, . to .) ().
One randomized trial, the FIT Long-Term Extension (FLEX), addressed the effect of BP use beyond  years and ST/FS-rad risk. The trial randomized  women who had an average of  years of prior alendronate use in the FIT trial () to  more years of alendronate or to placebo. Radiographic reports were evaluated to ascertain ST/FS-rad fractures. There were three ST/FS-rad fractures, two in alendronate (. per , py) and one in placebo (. per , py) (RH, .; % CI, . to .), and therefore the increase in risk was not significant, although with only a small number of events, CIs are wide. The upper bound of the CI (.) provides an upper bound for the risk ratio of  vs  years of alendronate use on ST/FS-rad.
A meta-analysis () also examined duration of use by comparing use for $ years vs shorter periods and found a significant risk ratio of . (% CI, . to .), but only four studies were included, none with x-ray-adjudicated AFFs.
The differences in findings between studies of AFFs and those of ST/FS-icd or ST/FS-rad are not incompatible; they merely suggest that the number of excess AFFs with long-term treatment is small enough to be offset in full by reductions in classical subtrochanteric or femoral shaft fractures.
Summary of treatment duration
Despite the limitations noted above, the evidence from these studies is convincing that longer-term use of BPs increases AFF risk more than does shorter-term use.
High-dose BP treatment in oncology and AFFs IV BPs are commonly used in patients with breast cancer, multiple myeloma, and some types of cancer and have been shown to reduce the skeletal-related events, fractures, and hypercalcemia (-). Zoledronic acid is most commonly used, although pamidronate is also sometimes used. Zoledronic acid ( mg in oncology) may be dosed monthly, resulting in much higher cumulative doses than in osteoporosis patients ( mg/y). To the extent that higher cumulative dose might increase AFF risk, there could be much higher AFF risk among these patients. There are three studies, as well as several case reports, about AFFs in cancer patients (-). In a study at MD Anderson Cancer Center, the rate of AFFs among cancer patients with BP exposure between January  and December  was analyzed in a retrospective analysis (). Oral and IV BP exposure was recorded from the electronic medical records at MD Anderson. Twentythree AFF cases were identified among , patients who had BP exposure, resulting in an incidence rate of . AFF cases per , py, much lower than reported for BP users at osteoporosis doses. A study at Memorial Sloan-Kettering examined AFFs among patients who received a minimum of  doses of pamidronate or zoledronic acid for secondary skeletal malignancy (). They found  people who met this criterion and four AFFs among this group and concluded that AFF incidence was low despite very high BP doses. A study at KPNC analyzed patients with breast cancer or myeloma given IV BP treatment between  and  (). The identified  patients in this cohort who had femur fractures with a median  IV BP doses spanning a median of . years. Among this cohort, they found six AFFs. Although they did report the number of cancer patients who had been treated with IV BPs, the number is likely quite high. They concluded that the incidence of AFFs in their population among patients receiving IV BP for cancer was very low. The three studies all report a very low incidence of AFFs and, although a direct comparison with osteoporosis populations cannot be made, the incidence in the cancer patients is not higher and may be lower. This despite the very high exposure to BPs. One possible explanation is that the dose of BP may not be so important compared with longer duration: few cancer patients had exposure . years. Another possibility is that IV BPs may be less related to AFFs than are oral BPs. Edwards et al. () hypothesized that the incidence of AFFs in cancer patients may be lower because most of the drug is consumed by active areas of skeletal metastasis, leaving less to affect other skeletal sites. The relevance of these results in cancer patients to osteoporosis is not clear, but they do suggest that the pathogenesis of AFFs is more complex than has been hypothesized.
AFF-like fractures in other bones
There have been scattered reports of fractures in bones other than the femur in BP users that share some of the characteristics of AFFs. These individual case reports have included fractures of the ulna, humerus, tibia, and clavicle that were associated with low trauma and had transverse morphology (-). The relationship between low-energy humeral shaft fractures and BP use was studied in a small case-control study of  cases and found association of BP use with lowenergy humeral fractures (). A systematic review of ulnar fractures in  yielded seven cases (). Five of the seven were Asian, with most being very elderly (all . years of age) with very long-term BP use ( to  years) and limited mobility. The authors hypothesized that these may have resulted from excessive repetitive stress on the ulna due to reliance on walking aids. Given the paucity of reports of ulnar and other nonfemoral fractures, these fractures must be exceedingly uncommon, although it has been suggested that clinicians should be aware of such possibilities (). (year  of denosumab treatment) and one in the crossover group during year  of the extension (year  of denosumab treatment) ().
Impact of non-BP osteoporosis treatments on AFFs
Odanacatib. Odanacatib is an inhibitor of cathepsin K, an osteoclast-secreted protease that degrades type I collagen, the major component of the organic bone matrix (). Odanacatib has shown greater reduction of bone resorption than bone formation, and unlike BPs, after a few months of treatment, bone resorption and bone formation were less strongly coupled. Data showed a stable % reduction in C-telopeptide of type I collagen with a temporary decrease in PNP which was progressively back to baseline levels at  years of treatment (). However, although there were promising results in terms of fracture risk reduction (), the development of the drug was discontinued due to an increased risk of cardiovascular events (). In the phase  LOFT trial involving nearly , postmenopausal women, AFFs were reported for five patients in the odanacatib group vs none in the placebo group (, ).
Full results of this trial have not yet been published.
Romosozumab. Romosozumab is a humanized monoclonal antibody against sclerostin, an osteocyte-derived glycoprotein that inhibits osteoblast differentiation and function, thereby increasing bone formation (). Blocking sclerostin action also lowers the RANK ligand/osteoprotegerin ratio, resulting in a decrease of bone resorption with bone biopsies, demonstrating that the latter effect becomes dominant after  months of treatment (). The antifracture efficacy of romosozumab has been shown in two RCTs: the FRAME study and ARCH study (, ). These trials also confirmed that romosozumab causes a rapid increase in PNP during the first weeks of treatment, followed by a significant and stable decrease up to  year of treatment. Also, C-telopeptide of type I collagen levels were decreased by % throughout the study (, ), consistent with a decrease in bone resorption (-), leading to rapid, large increases in BMD (, ). The drug is currently under review for approval. Unexpectedly, there was one positively adjudicated event of AFFs after  months of romosozumab treatment, a time when bone-forming effects dominate. Although the trial was  months in duration and romosozumab was administered only during the first  months, concerns have been raised about how frequent AFFs might be with longer use of the drug ().
Summary of epidemiology of AFFs
A large number of epidemiologic studies of various designs have addressed AFFs, particularly their relationship to BP use ( Table ) . The very low incidence of AFFs creates a challenge to its study. Another challenge is that people with low BMD and/or high fracture risk are both more likely to take BPs and are more likely to have osteoporotic fractures, including AFFs. Parsing out the impact of the underlying risk from the effect of the medications is very challenging owing to lack of adjustment for fracture risk in most studies. Furthermore, interpretation of the epidemiologic literature is challenging due to variations in study design and types of endpoints, some based on radiograph review but many using ICD-coded ST/FS fractures. Despite these limitations, for several of the key issues, at this time, some consistent patterns are evident:
• The incidence of AFFs is very low-many times lower than proximal femur and other osteoporotic fractures that can be effectively prevented by BP treatment. For example, as illustrated in • In general, there is a consistent relationship between any use of BP and an AFF. A meta-analysis showed a modest relative risk for any use of BP of ., but with significant heterogeneity across studies from a relative risk of . to a relative risk .. Better designed cohort studies with radiographic confirmation are needed to obtain more precise estimates of relative risk.
• There is good evidence from studies with radiographic confirmation that the incidence of AFFs increases with longer duration of BP treatment, particularly after~ years.
• Drug holidays (temporary discontinuations for  to  years) are recommended for some patients. Because longer-term continuation decreases vertebral fracture incidence further, those at higher risk of fracture (particularly vertebral fracture) would most benefit by continuation whereas others might take a drug holiday.
• AFFs have been seen with other types of treatments, including denosumab, odanacatib, and romozosumab, but the incidence relative to BPs is unknown. These observations cast doubt on the hypothesis that AFFs occur solely due to oversuppression of bone remodeling.
• There is an urgent need for better designed cohort studies with radiographic-confirmed AFFs that can control for important risk factors, particularly BMD and previous fracture history, which likely confound the relationship of treatment to AFFs and have not been available in cohort studies to date.
Pathogenesis
Thoughts on the pathogenesis of AFFs Bone remodeling is a continuous process characterized by coupled bone resorption and formation. In older adults and particularly in postmenopausal women, bone remodeling becomes imbalanced, with resorption outpacing formation. This imbalance leads to decreased bone mass, microarchitectural deterioration, and increased skeletal fragility. BPs inhibit osteoclastmediated bone resorption, initially reversing this imbalance as bone resorption is decreased, whereas bone formation continues, allowing the filling of resorption pits that were present prior to BP treatment and inhibiting any new resorption pits. The net result is an increase in bone mass, an inhibition of further decay in bone microstructure, and a reduction in fracture risk. With continued BP administration, bone formation is reduced along with bone resorption, and the rate of gain in BMD decreases. Further increases in BMD with longer duration administration of BP are likely due to increased mineralization of the bone matrix. Notably, the reduction of bone remodeling is a hallmark of BPs and has been associated with efficacy in fracture reduction (). However, as reviewed above, epidemiological studies have reported an association between long-duration BP use and AFFs. The implication from these reports is that in some individuals extended BP use alters bone composition and mechanical properties, including the initiation and/or repair of microdamage, leading to an increased risk of AFFs. Inconsistent with this theory, however, are reports that AFFs occur in patients who have never been exposed to BPs, and in patients who have taken other therapies that either induce bone formation (in the case of romosozumab) or that exhibit a lesser degree of bone remodeling Table 6 . Summary of AFF Epidemiology Many epidemiologic studies have addressed AFFs and their relationship to BP use. Studies are challenging due to very low incidence of AFFs, confounding by indication and lack of adjustment for BMD or fracture risk, varying definitions of AFF, and varying study designs. Despite these limitations, some consistent patterns are evident:
• The incidence of AFFs is very low, many times lower than hip, vertebral, or other osteoporotic fractures. For example, the number of AFFs is about 3 to 5 per 1000 hip fractures.
• Meta-analysis supports a significant relationship between any use of BP and AFFs. The size of the relative risk in the meta-analysis is quite small (1.7) but varies dramatically across studies for reasons not fully understood.
• There is consistent evidence from studies with radiographic confirmation that the incidence of AFF increases with longer duration of BP treatment, particularly after~5 y.
• Drug holidays (temporary discontinuations for 3 to 5 y) are recommended for some lower-risk patients.
• AFFs are not limited to BPs and have been seen with other types of nonantiresorptive treatments but incidence is unknown, casting doubt on the hypothesis that AFFs occur solely due to oversuppression of bone remodeling.
There is an urgent need for better-designed cohort studies with radiographic confirmation of AFF, controlling for key risk factors, particularly BMD and previous fracture history, which likely confound the observed relationship of treatment to AFFs.
inhibition than is seen with BP (in the case of odanacatib). Some have suggested that AFFs are a type of osteoporotic fragility fractures (). Thus, although the pathogenesis of AFFs remains unclear, in the following sections we review the unique features of AFFs that lend clues to their etiology, review the effects of BPs on the mechanical properties of bone, and highlight areas where more research is needed.
Implications of AFFs as stress or insufficiency fractures
Most fragility fractures occur following a single overloading event, wherein the forces applied to the bone, often due to a fall, exceed its strength. This is clearly the case for wrist and hip fractures and for at least a proportion of vertebral fractures. However, the nature of AFFs appears to be different from traditional fragility fractures, as many occur following minimal to no trauma, including absence of a fall-related event. This observation, in combination with the radiologic appearance of AFFs, particularly incomplete AFFs, suggest that AFFs resemble stress or insufficiency fractures. The progression of stages of an AFF, showing its similarity to a stress fracture, is shown in Fig.  . Stress fractures occur when a bone is unable to repair the damage associated with repetitive loading, and they occur commonly in the lower extremity in runners and soldiers undergoing initial military training (). A stress fracture is thought to occur due to excessive loading of a relatively healthy bone, whereas an insufficiency fracture occurs with normal loading of an abnormal or weakened bone (). Notably, AFFs share common features with stress or insufficiency fractures, namely their slow progression (), tenderness at the fracture site (e.g., prodromal thigh pain in the case of AFFs), a fracture line nominally perpendicular to the long axis of the bone, and radiographic signs of a cortical callus and repair. Indeed both AFFs and stress fractures show a periosteal callus, and at advanced stages, a radiolucent line across the cortex. Given their broad similarities, it is useful to consider the basic etiology of stress fractures and how it may relate to the development of AFFs. In the case of stress fractures, in response to novel or increased repetitive loading, bone remodeling increases, perhaps to replace fatigue-damaged bone, whereas simultaneously creating temporary cortical porosity. Increased loading also elicits bone modeling, or adaptive bone formation, which can reduce the stresses experienced in the bone. Inhibition of either of these processes, namely remodeling or modeling-based adaptive bone formation, theoretically has the potential to impact the development of a stress or insufficiency fracture.
Potential impact of BPs on stress fracture healing
The initial phases of stress fracture repair, namely stabilization of the crack by endosteal or periosteal bridging of the crack, do not appear to be influenced by BP treatment (). However, the subsequent steps in stress fracture healing and complete repair of the fracture require coupled bone remodeling (). BPs are known to localize at sites where bone turnover is high, which would include a healing fracture site. Therefore, it has been suggested that by reducing bone remodeling preferentially at this site, BPs could theoretically negatively affect the repair of microdamage and impending microcrack (). Over time, this inhibition of repair mechanisms could allow the crack to progress and/or coalesce with other cracks to create a stress fracture. In this scenario, cessation of BP may halt the accumulation of BP at the healing stress fracture site and allow repair to progress. In support of this hypothesis, two clinical studies have suggested that discontinuing BP reduces risk of subsequent AFFs (, ).
Contribution of mechanical loading and femoral geometry to AFFs
Excessive loading, such as that observed in athletes and members of the military who suffer stress fractures, is unusual for patients with AFFs. However, a few observations point to mechanical loading as a contributor to AFF pathophysiology. First, women who suffer AFFs are, in general, younger, than those who suffer hip and typical diaphyseal fractures. It is possible that their presumed higher activity level contributes to more and perhaps higher magnitude loading of the femur. Second, whereas femoral stress fractures generally occur in the medial cortex, AFFs initiate in the lateral femoral cortex, where tensile stresses are highest. Also noteworthy are observations that when AFFs are bilateral, they tend to occur in nearly identical locations in both femurs (, -). Moreover, the location of an AFF along the diaphysis seems to be affected by femoral shape, suggesting that subject-specific femoral geometry may influence femoral strain patterns, and thus the risk for AFFs and their location. Biomechanical analyses indicate that tensile stresses are high in the lateral femoral cortex (), and that these stresses are dictated not only by femoral geometry but also by the mechanical axis of the entire lower limb. AFFs have been reported to occur at the region of highest tensile stress distribution in the femoral shaft, suggesting tensile failure of the cortical bone (). A femur with greater lateral curvature (or bowing) would be predicted to experience greater tensile stresses than a femur of similar size, but straighter configuration ().
A growing number of studies support an association of femoral geometry, particularly greater femoral bowing and varus alignment, and AFFs. The precise location of the region of highest tensile stress will vary with femoral morphology, and accordingly may be influenced by race/ethnic origin. Several studies have suggested that AFFs are associated with an increased anterolateral femoral bowing, with a further association between femoral bowing and the fracture location along the diaphysis (-). For example, standing low-dose radiographic imaging revealed that lateral femur bowing is more pronounced in AFF patients than in controls matched for age, ethnicity, and duration of BP use (2.°vs 2.°, P = .). Moreover, standing femorotibial angle, a measure of the mechanical axis of the lower limb, is larger in those with AFFs than in patients with typical femoral fractures and is associated with fracture location along the diaphysis. Patients with AFFs are reported to have a more varus hip geometry (e.g., smaller neck-shaft angle, greater femoral offset) (Fig. ) and a narrower femoral neck width compared with patients with typical femoral fractures (-). Although preliminary and limited in nature, taken together, these studies suggest that aspects of femoral geometry that are predicted to increase tensile stresses in the lateral femoral cortex may contribute to the development and location of AFFs.
Effect of BPs on bone mechanical properties
Epidemiologic studies suggest that longer duration BP use is associated with increased risk of AFFs. Thus, one pathophysiologic mechanism that has been proposed posits that accumulation of BP in the bone matrix and/ or long-term inhibition of bone remodeling lead to negative effects on bone mechanical properties (). Whole-bone mechanical properties are determined by bone size (or mass), its macrostructure and microstructure, and the intrinsic properties of the bone matrix (). In turn, the intrinsic properties of the bone matrix are determined largely by the degree of matrix mineralization, the type and extent of collagen cross-linking, as well as the amount and nature of accumulated microdamage (). Generally speaking, the degree of matrix mineralization influences the preyield intrinsic mechanical properties (such as elastic modulus), whereas characteristics of the organic matrix (i.e., the collagen cross-links) modulate bone toughness, or the ability of the bone material to resist deleterious crack growth and absorb energy prior to failure.
It has been posited that by reducing bone turnover, BP treatment may lead to increased and more uniform matrix mineralization and accumulation of microdamage and nonenzymatic collagen cross-links, thereby negatively impacting bone matrix properties and contributing to the pathogenesis of AFFs ().
Studies in this area are broadly of two types: () animal models, where bone tissue can be readily obtained for experimental procedures; and () evaluation of human bone biopsies from individuals treated with BP.
Studies in animal models
As noted previously, treatment with BP reduces fracture risk by reducing bone turnover, increasing BMD, and stabilizing bone microstructure. Consistent with this, the vast majority of animal studies, including those required by regulatory agencies for drug registration, show either positive or neutral effects of current osteoporosis therapies on bone mechanical properties (). In particular, studies of BPs, denosumab, and odanacatib in ovariectomized primates have reported either positive or no effect on the intrinsic properties of cortical and trabecular bone.
In a series of studies in estrogen-replete beagle dogs, Burr, Allen, and colleagues were among the first to comprehensively examine the effect of  to  years of both clinical and supraphysiologic (fivefold higher than the clinical dose) doses of alendronate and risedronate on bone remodeling, microdamage accumulation, collagen cross-linking, and bone mechanical properties at several skeletal sites (-). These studies confirmed that BP treatment leads to increased bone mass and improved or maintained bone structural properties, concomitant with an increase in microdamage (, , ). Notably, however, there was no evidence of deficits in the tissue level properties of cortical bone for clinically relevant BP exposures (). In one instance, whole vertebral toughness was reduced~% in BP-treated dogs (); however, note that statistical significance was only achieved by combining the alendronate and risedronate groups in post hoc analyses. A recent study by Allen et al. () reported no reduction in vertebral toughness with alendronate treatment. Furthermore, the relevance of this finding to AFFs, which initiate in cortical bone, is unclear.
The studies consistently showed microdamage accumulation in trabecular bone, but not cortical bone, of BP-treated dogs (, , ), although the bone mechanical properties were unrelated to the amount of microdamage (, ), and longer duration treatment did not lead to more microdamage accumulation ().
These beagle dog studies also revealed that by reducing remodeling, BP may alter the organic composition of the bone matrix, which as noted above can influence bone mechanical properties. In particular, Tang et al. () reported an increase in nonenzymatic collagen cross-links, with an associated reduction in energy absorption in tibia cortical bone after  year of BP treatment. These effects only occurred in dogs treated with supraphysiologic doses of BP and were not observed in the dogs treated with the clinically relevant doses of BP. A subsequent study employed synchrotron x-ray imaging of cortical bone from the humerus of dogs treated with a clinically relevant dose of alendronate for  years (). They confirmed the prior observation that BP treatment increases nonenzymatic collagen cross-linking; however, BP treatment did not adversely affect crackinitiation or crack-propagation toughness.
One study has employed a novel type of mechanical testing, namely repetitive, cyclic loading, to assess the fatigue life of cortical bone from the same beagle dogs treated with either a clinically relevant or supraphysiologic dose of alendronate (). Using cortical bone specimens from the dog rib, they reported no effect of the clinically relevant alendronate dose on fatigue life of cortical bone, but reduced fatigue life in dogs treated with supraphysiologic doses of alendronate. These findings are notable, given the nature of AFFs as stress, or fatigue-related, fractures. However, the results remain controversial and difficult to interpret (), and they require confirmation in other studies.
Studies in human bone tissue
Whereas several studies have examined bone tissue composition, mineralization, and micromechanical properties using iliac crest biopsies from BP-treated subjects (-) (-), only a few have reported bone composition and nanoscale mechanical properties of femoral bone tissue from BP-treated individuals and/or patients with AFFs (-). Furthermore, only a single study has evaluated bone tissue composition and micromechanical properties in femoral cortical bone in patients with AFFs ().
Studies from iliac and femoral biopsies report that, as expected with a reduction in bone turnover, BP treatment leads to small increases in bone matrix mineral density, along with reducing the mineralization heterogeneity (, , , , ). Increased mineralization is expected to confer higher bone tissue stiffness and strength, and in at least one study, it returned the tissue mineralization to premenopausal values (). Moreover, in a study with iliac biopsies acquired before treatment, as well as  and  years after BP treatment, there was no further increase in mineralization between  and  years, suggesting that nonphysiologic hypermineralization of the bone matrix does not occur with BP treatment (). Data from the FLEX study, where patients were treated with alendronate up to  years, found no negative effects of alendronate on tissue mineralization or homogeneity of mineral content (). Alendronate treatment increased bone tissue mineralization density distribution up to normal levels, an effect that lasted up to  years without detrimental effects. The heterogeneity of mineralization and the percentage of low or highly mineralized bone areas were not different for the patients who were on treatment for  or  years vs healthy controls ().
By altering the rate of remodeling, BP treatment also influences the organic matrix. In particular, cortical bone (from iliac crest biopsies) from patients with long-term alendronate treatment exhibits higher collagen maturity than do treatment-naive patients (). Similarly, cortical bone obtained at the site of fracture in patients with AFFs was also recently shown to have greater collagen maturity than that from patients without fractures (), although femoral cortical bone from patients on long-term BP treatment did not exhibit higher nonenzymatic cross-links (i.e., advanced glycation end products) ().
To date, studies disagree regarding the influence of BP treatment on human femoral bone micromechanical properties. In particular, Zimmerman et al.
() reported improved nanoscale mechanical characteristics in femoral bone specimens from BP-treated women compared with treatment-naive women with osteoporosis. In contrast, Lloyd et al. () reported that BP treatment led to a deficit in the intrinsic toughening mechanisms in cortical bone, rendering it possibly susceptible to fatigue fracture. Furthermore, among patients exposed to BPs, those who presented with AFFs had greater cortical bone hardness than did those who had typical fractures (). Although these studies provide new insight into the possible pathogenesis of AFFs, they suffer from small sample sizes (, per group, and in some cases , per group). Moreover, in the study by Lloyd et al. (), it was not possible to include femoral biopsies from patients with osteoporosis who were not treated with BPs, and thus a clear distinction between the role of osteoporosis and of osteoporosis treatment could not be made.
Summary and unresolved questions regarding AFF pathogenesis
BPs have been widely and successfully used for the last  years to decrease the risk for hip, spine, and other fractures ( Table ) . However, AFFs do occur and are likely related to BP use, yet their pathogenesis remains uncertain. Although some studies suggest that BP may alter intrinsic properties of cortical bone, these findings are far from conclusive, and it is clear that AFFs are a rare event that occurs in only a tiny minority of patients who take BP. Moreover, challenging the theory that BPs are the sole culprit are reports that AFFs occur in patients who have never taken BP, and in patients on other therapies that either induce bone formation (in the case of romosozumab) or that exhibit a lesser degree of remodeling inhibition that is seen with BP (in the case of odanacatib).
Collectively, the current evidence strongly suggests that subject-specific characteristics-yet to be identified-that increase susceptibility to AFFs must play an important role. Indeed, it is likely that an AFF requires a "perfect storm" of factors, perhaps some underlying genetic differences in the response to BP, altered femoral geometry, a higher BMI and greater level of physical activity, and an altered mineral/matrix composition at baseline, perhaps altogether, to initiate an AFF [ Fig. (a) and (b) ]. Clearly more work is needed, and as highlighted in the ASBMR Task Force reports, a comprehensive registry could be extremely helpful in sorting out this complicated pathophysiology.
In summary, the pathophysiology of AFFs remains uncertain, and available data cannot fully explain the clinical "paradox" of AFFs: why BPs effectively reduce • AFFs do occur and are likely related to BP use, but their pathogenesis remains uncertain.
• Although some studies have suggested that BPs may alter intrinsic properties of cortical bone, this could not explain why AFFs only occur in a tiny minority of patients.
Further challenging the notion of universal BP harm is that AFFs occur in patients that have not taken BPs and in patients on other types of therapies, including some that do not reduce bone resorption.
• The current evidence suggests that patient-specific characteristics must play an important role and that AFFs likely require a combination ("perfect storm") of these factors. Although these factors are not fully identified, they may include femoral geometry, genetic effects, BMI, physical activity, and others.
• A registry of AFF cases, as recommended by the ASBMR task forces, could be helpful to sort this complex pathophysiology.
• Overall, the pathophysiology of AFFs remains uncertain, and current data cannot explain the clinical paradox of AFF: why BPs effectively reduce fracture risk in many fracture types while being harmful at a single fracture site, only in a small minority of patients.
fracture risk for many types of fracture but become harmful at a single fracture location only in a small percentage of individuals. More studies are needed to determine how and why the effects of BPs may increase risk of AFFs in a small minority of patients and, importantly, which individuals are at higher risk.
Risk Factors
Identifying specific risk factors for AFFs could guide a physician's choice of medications or prompt closer clinical monitoring of candidates initiating treatment or those already on osteoporosis treatment. However, studies establishing the effect of specific risk factors are challenging, both due to the relatively low incidence of AFFs and the retrospective, observational nature of most available studies, which have often yielded conflicting results. Additionally, there are few studies that have controlled for factors that may confound the relationship of the risk factors to AFFs. The following factors have been proposed as potential contributing factors that could influence the risk of developing AFFs in BP-treated populations. Because AFFs represent only a small minority of all ST/FS-icd fractures, the section below focuses on evidence for risk factors in studies in which AFFs were adjudicated from radiographs.
Comorbidities
Several studies have investigated whether an association exists between specific comorbidities and AFFs.
Diabetes mellitus and weight
Diabetes mellitus (DM), either type  or type , is associated with an increase in the risk of fragility fractures and altered bone turnover, and bone material properties may play roles in this increase (). A recent meta-analysis concluded that low bone turnover (both formation and resorption) appears to be a common, although not a universal, finding in type  and type  DM (). Given the potential relationship of DM to bone turnover, DM could play a role in AFF risk. When considering population-based studies with AFF outcomes assessed from radiographs, only a single small study has shown evidence that DM is associated with higher AFFs, whereas several larger studies suggest that patients with diabetes are at lower AFF risk. In a retrospective case-control study of patients with low-energy ST/FS-adj fractures and patients with hip fractures matched for age and sex, Giusti et al. , who reported DM prevalence of % in AFF cases vs % in non-AFF controls. Overall, these findings suggest that DM is not a risk factor for AFFs.
Regarding BMI, there are limited data to address the relationship of BMI to AFF risk. One study showed no relationship of BMI to AFF () whereas another showed no relationship of BMI to ST/FS-rad fractures (). Alternatively, a recent study in Korea showed that  AFF patients had higher BMI than did non-AFF ST/FS controls (, ).
Rheumatoid arthritis
Rheumatoid arthritis (RA) was first proposed as a potential risk factor for AFFs in  (). At first this may seem surprising, as RA is a strong risk factor for classical osteoporotic fractures and enhances osteoclast number and activity, thus favoring a high turnover state with accelerated bone resorption (). However, use of large doses of glucocorticoids (GCs) that lower bone turnover may explain Giusti et al.'s findings. Later studies have not consistently found an association of RA with AFFs. In a Swedish study, there was no difference in the prevalence of RA in BP users with AFFs (%) or BP users without AFFs (%) (). Similarly, in KPNW, RA was reported in a similar proportion in cases (.% of AFF cases) vs controls (% in non-AFF femoral shaft fracture controls) (). Thus, there is little evidence that RA is a risk factor for AFFs.
Genetics
Given their rare occurrence, even among BP users, it has been proposed that susceptibility to BP-related AFFs may have a genetic component. Bhattacharyya et al. () investigated coding variations in the ALPL gene and serum levels of alkaline phosphatase in  patients who sustained AFFs after a mean exposure of BPs of  years and  control subjects with similar length of BP use who had not sustained AFFs, but they found no differences between these two groups in terms of alkaline phosphatase serum levels or gene polymorphisms. A genome-wide association study analysis in  patients with AFFs and  controls with and without osteoporosis identified a number of gene variations that may contribute in a polygenic manner to the susceptibility of AFFs (). Recently, exome sequencing in three sisters treated with BPs who suffered AFFs has identified mutations, now shown to impair enzyme function, in three components of the mevalonate pathway (MVD, GGPS, and CYPA), the very pathway targeted by BPs to inhibit bone resorption (). The fact that this pathway is the target of nitrogen-containing BPs suggests that these mutations, by mimicking or amplifying BP action, may predispose patients to AFFs. Importantly, note that the patients had other shared mutations and that at this time the mutation in question has not been reported in other AFF cases. Furthermore, the CYPA gene was mutated in all three sisters. Polymorphisms in this gene have been previously found to be associated with low bone mass and increased estrogen catabolism (). Further studies are needed to assess the prevalence of these mutations and whether they are associated with an increased risk of AFFs in other populations.
Findings that genetic abnormalities may play a role in AFFs need to be corroborated in other populations, and a collaborative effort to collect and share DNA material from such patients would be of great interest and advance the field. Other studies are needed to determine whether there are other mutations or polymorphisms that may increase risk of AFFs, particularly when BPs are used, and, more generally, determine whether genetics plays a significant role in AFFs. However, two factors may confound the relationship of GC use to AFF risk, that is, the reason for GC use and use of BPs. Diseases for which GCs are used in high doses or longer duration (e.g., RA) may in and of themselves increase risk of fractures, including AFFs. With respect to BPs, guidelines suggest that BPs should be prescribed for those postmenopausal women and older men, particularly when they are on higher doses of GCs (). Thus, it is probable that those on higher doses of GCs may also be more likely to be using BPs, and therefore consideration of these two factors separately will fail to account for this potential confounding. There are few data to address this question and no rigorous multivariate analyses. To disentangle these relationships, studies with rigorous simultaneous adjustment for multiple risk factors are needed to definitely assess the relationship of GCs to AFF risk.
Medications
GC use
In summary, the variety of durations, doses, and conditions for which GCs are used complicates the assessment of the relationship of GCs to AFFs. Despite this limitation, most studies report a significant association of GC use with AFFs. Additional studies are important to examine more precisely the relationship of dose and duration of previous GCs to AFFs and to define interactions between GC use and other risk factors. This information would enable clinicians to use information about GC use to help evaluate AFF risk.
Proton pump inhibitors
It is not clear whether proton pump inhibitor (PPI) use is a risk factor for AFFs. Although initial case reports suggested use of PPIs in several patients, additional studies have not shown an important association. There was only a slightly higher use of PPIs in patients with AFFs compared with non-AFF controls (or without AFFs in the Swedish analyses) (% vs %) that could likely be due to confounders such as age and BP use (). In the KPNW study (), PPIs were less commonly used in AFF cases compared with non-AFF ST/FS-adj fracture controls, although the difference was not significant.
Race
Several studies have shown that the risk of AFFs is strikingly increased in subjects of Asian origin (living in North America or Europe) compared with European origin. A study of KPSC patients showed that although % of the  AFF cases were of Asian descent, Asians represented only~% of the underlying population (). In a study within KPNC, Lo et al. () reported an adjusted RH for Asian ethnicity for AFFs of . (% CI, . to .). Other studies have also reported a higher prevalence of AFFs in Asians (, ). These reports have all been from studies in North America or Europe. Whether the same increased risk applies to Asians living in Asian countries is unknown, but note that the many of the first AFF case reports arose from Singapore ().
Alternatively, a recent study reported a low prevalence of AFFs in Korea ().
Several explanations for the increase seen in Asians in North America have been proposed and are being studied. As mentioned in the "Pathogenesis" section, bone geometry (i.e., greater curvature of the femoral shaft) could contribute to an increased risk for AFFs in this population (). Consistently, abnormal lower limb alignment, including the genu varus and genu valgus, were found to be significantly associated with AFFs in Korean women (). Other possible factors that may increase risk in Asians include ethnic-related differences in BP pharmacokinetics, drug adherence, or a younger age at the time of initiating treatment (), although these all remain speculative at this point. Taken together, existing epidemiological studies suggest that, similar to hip fractures, the risk of AFFs increases with age in BP-treated subjects, with BPs delaying the occurrence of hip fractures and accelerating the occurrence of the rarer AFFs.
Generalized cortical thickness
Several of the original case reports of AFFs reported that cortices seemed generally thicker than might be expected (). A generalized increase in cortical thickness of the femoral diaphysis is classified as a minor feature sometimes associated with AFFs in the ASBMR document (). However, there are limited data from epidemiologic studies to support a general increase in cortical thickness as a risk factor for AFFs. An association between general cortical thickness and AFFs was seen in two studies (, ), but no association was observed in several other studies (, -).
One possible explanation for generally thicker cortices being a risk factor for AFFs is that long-term BP increases overall cortical thickness, at least in some patients. This relationship was examined in a prospective study in which Chen et al. () assessed the effect of BP use and duration on cortical thickness and compared the cortical thickness of healthy volunteers, short-term BP users, and long-term (. years) BP users. No differences in global cortical thickness were found among groups, and no significant correlation between the BP treatment duration and cortical thickness was apparent. No fractures were identified in this study.
In summary, most current data do not support a link between generalized thickening of the cortices and increased risk of AFFs.
BMD
There are limited and conflicting data on the influence of BMD on AFF risk. In the KPNW study, hip BMD was only available in about a third of the AFF cases and fewer of the non-AFF ST/FS-adj controls. However, the results showed that BMD was significantly higher in the AFF cases than in the non-AFF controls (hip T-score, 2. vs 2., respectively; P = .) (). Another small study also showed higher BMD in AFF cases vs controls (). However, Koh et al. () found no difference in the BMD of the total hip, trochanter, femoral neck, and lumbar spine between postmenopausal Korean women with AFFs and the control group. In a report of  AFF cases, Schneider et al. () suggested that in a sample of AFF patients, there was an overrepresentation of those with osteopenia rather than osteoporosis ().
Taken together, these data, although limited, suggest that low BMD might not be as predictive of AFFs, as it is for more usual osteoporotic fractures. There is some suggestion, requiring more research, that in some women with only moderately low BMD who have been treated with BPs, there may be a higher risk of AFFs. However, BMD is strongly related to age, as well as activity level and BP use, and the relationships among these three factors have not been fully explored. More research is needed particularly about the interaction of BMD, age, activity, and BP duration on AFF risk.
Physical activity
It has been hypothesized that the type of physical activity may affect AFF risk and the site of AFFs (, ). An explanation for the slightly younger age of those who develop AFFs may lie in the fact that by being more active, relatively young individuals engage in more activities that impose tensile loading to the femoral shaft, such as walking and stair descent (). However, there is no evidence that can address this question.
Further studies are needed to clarify whether specific physical activities or whether the level of weight-bearing activity in general influences the risk of developing an AFF.
Femur geometry
As discussed in the Pathogenesis section, the shape of the femur may be an important risk factor, with those with more bowed femurs having a higher risk of AFFs due to the concentration of stresses in the most bowed area of the femur. Presently, there is insufficient evidence to specifically quantify risk as a function of femur shape. Future studies are needed to provide more information about this potentially important relationship of femur geometry to risk of AFFs.
Risk factors summary (Table 8) • More information, including quantitative evidence, about the relationship of risk factors to AFF risk could be very important to allow clinicians to customize therapy or monitor AFF signs more closely in those at higher risk. This information could help clinicians in making decisions about initiation of BP treatment and about initiation and duration of drug holidays. However, at present, the evidence about risk factors is limited.
• Among potential risk factors, there is good evidence of a relationship between GC usage and Asian ancestry and higher risk for AFFs.
• On average, AFFs occur at a younger age than do hip fractures. Age is less strongly predictive of AFFs than it is for other osteoporotic fractures. However, the relationship of age to AFFs is likely confounded by covariables such as prior fracture, BMD, and ethnicity, so further data are needed to assess the extent to which age directly predicts AFF.
• There are limited data relating BMD to AFF risk, but these limited results suggest that BMD is less predictive of AFF than it is for other osteoporotic fractures.
• Although PPI use, diabetes, and RA have been suggested as possible risk factors, there is little evidence supporting their association with AFFs.
• Other clinical information discussed in the sections below, including prodromal pain and assessing cortical beaking by x-ray or extended dual-energy x-ray absorptiometry (DXA) imaging, could play an important role, together with risk factors, in future AFF risk assessment strategies.
Strategies to Decrease Risk of AFFs in Patients on BP Treatment
Drug holidays
The idea of a temporary discontinuation of BP therapy has been discussed as a possible strategy to decrease AFF risk associated with long-term treatment and to assuage patient concerns about AFFs. The ASBMR has proposed guidelines for these temporary discontinuations (termed "drug holidays") (). The rationale for a drug holiday rests on the assumption that AFF risk will be reduced whereas drug efficacy may be retained. Temporary discontinuation of treatment is relevant to BPs given their long-term residence in bone and residual effects after discontinuation (-) but is not advised for other types of osteoporosis treatments ().
Reduction in risk of AFFs with discontinuation
The value of a drug holiday is driven primarily by the hope that a temporary discontinuation will reduce risk of AFFs. Only the Swedish study has addressed this question (, ). The results suggested a % reduction in risk of AFFs within  year of discontinuation of BP. This risk reduction did not differ for shorter-term prior BP exposure. However, there are a number of methodologic limitations to this observational analysis, both in the choice of comparator group and in the lack of true long-term data on medication history. Data from several studies show that bone turnover increases somewhat in the year following cessation of oral BPs, although it remains far below pretreatment values (, ). However, discontinuing BP may not just increase bone turnover overall, but may stop the accumulation of BP at the AFF site and allow a stress fracture to heal. Although there is little direct evidence about the impact of BP discontinuation on AFF risk, these factors provide some rationale for how a temporary discontinuation could be beneficial for decreasing AFF risk. More data are needed to address this important question that bears directly on the value of drug holidays.
Retention of benefits during a drug holiday
An extension study to the FIT alendronate study (, ) randomized  patients with a mean -year previous exposure to alendronate to  more years of continued alendronate or placebo (). This study (FLEX) found that after discontinuation, bone turnover rose slightly but remained well below pretreatment levels. BMD decreased, but only slowly, and on average remained above pretreatment values for at least  years. Fracture risk for nonvertebral fractures was similar in those who discontinued treatment, although risk was higher for clinical vertebral fracture in those who discontinued treatment. A similar study looking at discontinuation of zoledronic acid after  years of annual infusion showed a similar result with perhaps slightly better retention of benefits for up to  years after discontinuation (). These two studies have lent support to the recommendation that those at lower risk of fracture can safely take a drug holiday without losing benefits of therapy. The drug holiday could last for  to  years but not . years. Given the minimal loss of benefits, temporary drug holidays after  to  years of BPs may be advisable for patients at lower risk of osteoporotic and hip fractures to alleviate concerns about AFFs, despite the limited data showing decreased AFF risk (, ). Note that the recommendations for BP discontinuation are most applicable to alendronate and zoledronic acid, but less certain for risedronate, ibandronate, and other BPs where is little evidence about impact of discontinuation.
Drug holidays are not advisable for non-BP antiresorptives such as denosumab and also for other medications including teriparatide (which is, however, restricted to a maximum duration of use of  months, after which antiresorptive treatment is used), raloxifene, and hormone therapy, as there is a rapid reversal of effect leading to large BMD losses and loss of antifracture efficacy soon after discontinuation (). For denosumab specifically, cessation is followed by a period of rebound high bone turnover, bone loss, and possibly an increased risk of multiple vertebral fractures (-).
Patient education about prodromal symptoms Prodromal groin or thigh pain has been reported in patients experiencing an AFF (, ). There are limited data about the frequency of prodromal symptoms from large studies owing to the retrospective nature of these studies. In a review of  case • Among risk factors, the evidence most strongly supports higher AFF risk in GC users and those of Asian ancestry in North America and Europe.
• AFFs occur on average at a younger age than do hip fractures: older age is much less strongly predictive of AFFs than other osteoporotic fractures.
• BMD is also more weakly predictive of AFFs than other osteoporotic fractures.
• PPI use, type 2 diabetes, and RA have been suggested as risk factors, but there is little consistent evidence supporting their relationship to AFF risk.
• Querying patients about prodromal pain and assessing cortical beaking by x-ray or extended DXA imaging in high-risk patients can be clinically useful.
• As more evidence accumulates, femoral geometry may prove more useful in identifying AFF risk.
• Better tools to predict AFF risk in patients on BP treatment could be very helpful to individualize therapy.
reports of AFFs (), just .% ( cases of  cases with information) reported prefracture pain. In the KPSC study, of the  AFFs identified, % had evidence from their medical record of reported pain in the groin or thigh (). The period of the report prior to a complete fracture varied from  to  months to several years (). Thigh or groin pain is included as a minor feature in the ASBMR case definition of AFFs (). It is important that physicians and patients are aware of the importance of symptoms of aching deep thigh or groin pain, and for physicians to query patients treated with BPs about this symptom. Any report of thigh pain in a long-term BP user should prompt further evaluation with radiographic imaging to rule out impending AFFs.
DXA imaging as a tool for monitoring cortical changes A recent study () examined the ability of extended femoral DXA scans to identify AFFs. Specifically, within a tertiary referral center,  people on antiresorptive therapy were screened by an extended femur DXA scan and those with signs of cortical beaking on the DXA scan were followed up with radiographs. A total of nine women with incomplete AFFs were identified, suggesting that use of extended femur scans may be useful to identify incipient or femoral lateral focal cortical thickening. This study lacked a control group of treatment-naive subjects who also had extended femoral DXA scans. Thus, more work is needed to identify the DXA scan features that might warrant radiographic follow-up, but this technique, perhaps in combination with assessment of prodromal pain, could be useful for identifying patients prior to complete AFFs, and thus may have a role in the followup for long-term BP users (, ). Recently, software has become available from the bone densitometry manufacturers that allows for extensions of the single-energy higher resolution DXA scans to the femoral shaft region and quantification of the extent of cortical beaking (Fig. ) , although only one formal study has included this technique. If future research supports the utility of extended femoral DXA scans, they could become part of routine care for patients on long-term BPs.
Clinical Evaluation and Treatment of Incomplete AFFs
Incomplete AFFs: clinical presentation The signs and symptoms of an incomplete AFF may be subtle. As stated above, patients present with prodromal symptoms of a dull ache in the thigh or groin region. A thorough history and physical examination should be performed for each patient in whom there is a suspicion of this fracture pattern. In patients with suspected AFFs, careful radiographic evaluation of the pelvis, hip, and femur should be performed bilaterally, as a substantial proportion of patients may have bilateral involvement (). As described in the ASBMR criteria, on plain radiographs, incomplete AFFs can be identified as thickening of the lateral cortex of the femur in the subtrochanteric region, a periosteal callus (or "beaking), and possibly a subtle fracture line, involving the lateral cortex. It is important to distinguish this fracture pattern from proximal femur stress fractures, most commonly seen in athletes or military recruits, which typically involve only the medial cortex (). If radiographic changes are not visualized in a patient complaining of thigh or groin pain with a history of BP use, advanced imaging such as MRI or a bone scintigraphy scan should be obtained as a more sensitive means of detecting an impending fracture (-). MRI is the most commonly used advanced imaging modality in patients with thigh pain who do not have typical radiographic features. Both T-weighted and T-weighted images will demonstrate focal cortical thickening along the lateral cortex of the femur with or without signal abnormality, a fracture line, and adjacent periosteal or bone marrow inflammation or edema. Short tau inversion recovery images may be particularly helpful in the detection of local inflammation or hyperemia (, ). For patients who cannot undergo an MRI owing to medical contraindications, a bone scintigraphy can be used to detect AFFs. In the setting of an AFF, bone scintigraphy will demonstrate increased uptake and local periosteal stress reaction at the lateral cortex of the subtrochanteric area (, ).
Recently, a scoring system has been developed with the goal of predicting which patients will progress from an incomplete to complete AFF (). This tool, which includes the location of the incomplete AFF in the lateral cortex, the severity of pain, status of the contralateral femur, and the extent of radiolucent line, may be particularly useful in deciding which patients are candidates for prophylactic surgery to stabilize their incomplete AFF.
Medical management of incomplete AFFs
There is consensus that for patients with a confirmed incomplete AFF, BPs should be discontinued (). Calcium intake and vitamin D levels should be assessed and supplements provided as necessary (). For patients with minimal pain, a trial of reduced weight bearing for  to  months with crutches or a walker is recommended (, ). Despite these guidelines, identification and subsequent medical management of an AFF is reported to be suboptimal ().
Prophylactic surgery for incomplete AFFs
Although nonoperative treatment of AFFs may be attempted in patients without a radiolucent fracture line on plain radiographs, patients with significant thigh pain and those with a radiolucent line on radiographs should be advised to undergo prophylactic intramedullary rodding to decrease the risk of complete fracture and improve functional and clinical outcomes.
Operative management of incomplete AFFs is becoming more widely accepted as the standard of care, as nonoperative treatment has been associated with poor outcomes (, , ). In a study of  patients with  incomplete AFFs, Egol et al. () found that the operative cohort had a % rate of radiographic union and % resolution of pain at a mean of . months after treatment. The nonoperative cohort had an % rate of radiographic union and only % resolution of pain at final follow-up (). In a similar study comparing nonoperative vs prophylactic intramedullary fixation of incomplete AFFs, Banffy et al. () found that prophylactic intramedullary fixation led to significantly improved outcomes and a reduced hospital admission time. Additionally, five of six patients treated nonoperatively progressed to fracture completion and required subsequent operative fixation ().
Treatment with teriparatide or other anabolic agents
To the extent that AFFs can be attributed to low bone turnover, there is a rationale to test whether anabolic therapy, which increases bone formation and resorption, might be beneficial to patients with incomplete AFFs. However, the limited current evidence is equivocal. In one of the first published clinical cases, a -year-old woman on BP for  years was treated with teriparatide after occurrence of thigh pain and bilateral incomplete AFFs. Sequential MRI and clinical evaluations revealed progressively less edema around the fracture, as well as complete healing and relief of pain at  months of treatment (). Several subsequent reports with larger groups of patients have, however, shown mixed results. For example, Cheung et al. () reported a series of  patients with AFFs who were treated with teriparatide. Three required surgery, but among the other ,  improved whereas the other  either did not improve or worsened. Therefore, given the paucity of evidence, the inconsistent results, and lack of randomized trials, there is not enough evidence to support an unequivocal beneficial effect of teriparatide (or other anabolic agent) on incomplete AFF healing. The  ASBMR report recommended that after discontinuation of BPs and maintenance of adequate calcium and vitamin D, it is reasonable for a physician to consider the possibility of teriparatide for a patient in whom an incomplete AFF is not healing ().
Complete AFFs: clinical presentation Patients with a complete AFF present in a similar fashion to patients with typical femur fractures, and they are first evaluated in the emergency room. As described in the ASBMR criteria, radiographs will commonly reveal thickening of the lateral cortex adjacent to the fracture site, a transverse or oblique fracture pattern starting laterally and extending medially, and a lack of significant comminution (). It is important to obtain radiographs of the contralateral extremity, as the diagnosis of an incomplete AFF on the contralateral side is frequently made at this time.
As all patients with a complete AFF and many with an incomplete AFF will require surgery, it is essential that the endocrinologist who treats osteoporosis has some familiarity with the surgical options, not only to be able to answer initial questions from the patient and relatives but also to know what to expect when consulting with the local orthopedic specialists. As described below, the treatment plan needs to be multidisciplinary and goes beyond the surgical procedure itself.
Surgical procedures
There are a variety of surgical techniques that can be used to stabilize both incomplete and complete AFFs. The techniques can be broadly classified as either extramedullary (i.e., plates and screws) or intramedullary fixation (i.e., intramedullary nails or rods).
In the setting of prior BP use, osteoclastic remodeling is inhibited and there is decreased potential for intramembranous fracture healing. This type of fracture healing is necessary following extramedullary fixation. Therefore, most orthopedic surgeons recommend the use of intramedullary nail fixation for the treatment of AFFs (, ). A cephalomedullary nail is a long intramedullary nail that spans the entire length of the femur and includes a screw that is inserted across the femoral neck and into the femoral head. This specific type of intramedullary device is a commonly used option for the treatment of AFFs, as it protects the entire length of the femur, including the hip, and theoretically reduces the risk of any future fracture risk. Despite the popularity of this implant choice, there are no RCTs to support the use of one fixation device over another in the setting of AFFs.
Postoperative treatment
After stable fixation with an intramedullary nail, most patients are made weight bearing as tolerated and encouraged to start early physical therapy and resume normal ambulation. In certain situations, the orthopedic surgeon may choose to delay full weight-bearing activity for  and  weeks after surgery, but this is avoided when possible. The patient will follow up with the orthopedic surgeon at regular intervals to obtain radiographs and assess fracture healing. Patients with an AFF are at a significantly higher risk of delayed healing, nonunion, and a need for secondary procedures compared with patients with typical femur fractures. In a study of  AFFs in  patients, Weil et al. () found that only % of patients healed their fractures following surgical treatment. The other % of patients required a secondary revision procedure to achieve fracture healing (). In a study of  patients with AFFs undergoing surgical treatment, Teo et al.
() found that .% did not heal and required a secondary procedure to achieve fracture healing. In  patients with  fractures, Cho et al. () reported a primary healing rate of .%, with a mean time to union of . months. These outcomes are significantly worse than those in patients treated for femoral shaft fractures without any history of BP use, in which the healing rates are reported to be .% (). The difference in these healing rates may be due to the history of BP use, and not to any difference in surgical technique or protocol, although a recent study identified the quality of fracture reduction as the most important determinant of the time to union of AFFs (). A recent study suggests that augmentation of the fracture with bone marrow aspirate concentrate may reduce healing time of AFFs treated with intramedullary fixation (). Additionally, several studies reported that postsurgical treatment with teriparatide tends to improve healing times and clinical outcomes (-), although the studies were small and underpowered and additional research is needed to optimize postsurgical outcomes in AFF patients. Nonetheless, patients being treated surgically for an AFF should be advised about the high risk of delayed healing and potential need for a secondary procedure. Additionally, given the high risk of delayed healing, a multidisciplinary team is necessary to optimize healing potential from both a medical and surgical standpoint.
Key Areas for Future Research (Table 9) . Despite the proven positive benefit/risk ratio for BPs in osteoporotic patients, there is widespread concern among patients, as well as clinicians, that BPs could cause more fractures than they prevent-a clear case of misinterpreting complex epidemiologic data and relative vs absolute risk. It is important to develop and implement public health efforts to educate patients and physicians that will eliminate the barriers to treatment and correct the osteoporosis treatment gap. . There are large gaps in our epidemiologic knowledge about AFFs due to limitations in study designs together with the AFF or ST/FS definitions that have been used. Studies are particularly cumbersome because AFFs do not have an ICD code, which could have facilitated epidemiology and pharmacovigilance. It is of critical importance that rigorously designed cohort studies that include evaluation of radiographs be performed. These will help to more precisely define AFF risks vs benefits and, importantly, to provide more information about risk factors that might lead to more specific clinical recommendations with respect to individualized treatment. . We have incomplete evidence about risk factors for AFFs among those starting or continuing on BPs. Better studies of risk factors are needed that can lead to development of AFF risk prediction tools. This could help clinicians individualize treatment duration and choice of medications so that the best possible benefit/harm ratio is achieved for individual patients. . Several strategies to evaluate patients on longterm BP therapy for AFF risk are being explored, including monitoring of focal thickening in the lateral cortex. More information about how these approaches may be predictive of AFFs and in whom and how frequently they should be used could help alleviate concerns about BP use. . We have an incomplete understanding of the pathophysiology of AFFs. Further studies are needed to help understand why BPs, which are extremely effective in reducing risk for most fractures in the vast majority of osteoporotic patients, paradoxically can lead to AFFs in some rare cases, and, moreover, why AFFs occur in those never exposed to BPs or those treated with therapies that are not purely antiresorptive in nature. . More studies of potential interventions for incomplete AFFs would improve clinical decisionmaking. The value of decreased physical activity and medical interventions, such as anabolic treatment, would be extremely helpful to help patients and clinicians decide when early surgical interventions are appropriate. . The currently accepted definition of AFFs is based on the ASBMR  criteria. However, application of several of the features and other aspects of the definition can be challenging, and we do not know whether their combination as proposed in the ASBMR definition is optimal. Further research to test and improve the radiological definition of an AFF to make it more straightforward, reproducible, and specific would be helpful to our understanding and clinical management of AFFs.
Summary and Conclusions
AFFs occur in the subtrochanteric or femoral shaft region of the femur and have been associated with BPs and other osteoporosis medications, but they also occur in treatment-naive patients. They occur with minimal or no trauma, are often proceeded by periods of thigh or groin pain, and bilateral involvement is commonly seen. However, they are rare, particularly compared with the hip and other osteoporotic fractures that BPs can prevent. Although the benefit/risk ratio for BPs is extremely favorable during  to  years, concern about AFFs is perhaps the largest factor responsible for the large decrease in use of BPs and other osteoporosis medications since  (creating the osteoporosis "treatment gap") (, ).
There are a large number of epidemiologic studies of various types, and although there are many challenges to studying such a rare condition, they support an association with BP use, particularly for longer duration of BP use, with increased AFF risk. AFFs have also been seen with osteoporosis agents other than BPs. However, there are specific gaps in our knowledge in several areas. Most importantly, we are uncertain as to the magnitude of the relationship between BP use and AFFs due to large variations in study results. More research in this area is urgently needed.
Many studies have addressed potential mechanisms that may be consequences of low bone turnover. These include lowered ability to repair microdamage, decreased heterogeneity of mineral, decreased toughness in bone, and others. However, there is not yet a satisfactory understanding of the essential paradox that although BP treatment reduces fracture risk in the vast majority of patients for a wide variety of fracture types, AFFs occur only at one fracture site, and then only in rare cases.
There seem to be specific risk factors that may place some patients at higher risk for AFFs. These include bone geometry (particularly greater femoral bowing), Asian race in North America and Europe, use of GCs, possibly some conditions such as diabetes, or genetic factors. Perhaps these risk factors, interacting with mechanisms described above, may create an unusual combination of circumstances in a very small number of patients to cause AFFs. However, these complex interactions between risk factors and potential mechanisms are not understood, and they should be high on the research agenda. • Although the greatly positive ratio fracture reduction benefits to AFF risk for BPs is evident, particularly for treatment to 5 y, usage of these effective therapies has dramatically decreased. It is important to develop and implement public health efforts to educate patients and physicians to correct the osteoporosis treatment gap.
• It is of critical importance that rigorously designed cohort studies including radiographic evaluation be performed to more precisely define the magnitude of AFF risks with BP use and to provide clinically useful information about risk factors to improve individualization of treatment.
• Development of AFF quantitative risk prediction tools to guide clinicians in BP use to achieve the best possible benefit/harm ratio in individual patients.
• Development of strategies to evaluate patients on long-term BP therapy for AFF risk, including standardized monitoring for groin pain and imaging (including extended DXA) of focal thickening in the lateral cortex. This could help alleviate concerns about BP use in general.
• Further studies are needed to help understand pathogenesis: why BPs, which are extremely effective in reducing risk for most fractures in the vast majority of osteoporotic patients, paradoxically can lead to AFFs in some rare cases, and, moreover, why AFFs occur in those never exposed to BP or those treated with therapies that are not purely antiresorptive in nature.
• More studies of potential interventions for incomplete AFFs are needed. The value of decreased physical activity and medical interventions, such as anabolic treatment, would be extremely helpful to patients and clinicians and would assist in deciding when early surgical interventions are appropriate.
• The currently accepted definition of AFF is based on the ASBMR 2014 criteria, but there are issues with its various aspects. Further research to test and improve the radiological definition of AFF to make it more straightforward, reproducible, and specific would be helpful to future research studies and clinical management of AFFs.
From a clinical standpoint, patients on BPs who report prodromal pain should be investigated through radiographs or other imaging for possible incomplete AFFs. It is generally recommended that when incomplete fractures are visualized, antiresorptive medications should be stopped and, in more serious cases, prophylactic surgery should be considered.
Temporary drug holidays after  to  years of therapy are appropriate for BPs [especially for alendronate (after  years) and zoledronic acid (after  years)] in patients at low risk of fracture. There are some data showing that discontinuation decreases AFF risk, and thus use of drug holidays could likely enhance the benefit/risk balance for a longer-term treatment course for osteoporotic patients. However, discontinuation for other antiresorptive medications, including denosumab, raloxifene, or estrogen, results in rapid loss of benefits and should be followed by some sort of continued therapy. Anabolic therapy is approved for up to  years and should be followed by an antiresorptive drug to retain benefits. More research about the impact of temporary BP drug holidays on AFF risk is needed.
In conclusion, AFFs are rare but remain a catastrophic event for some patients. The benefit/risk ratio is clearly in favor of BPs and other treatments in patients at high fracture risk. However, patient and clinician concerns have limited treatment among patients who could greatly benefit. Better communication with patients about the benefits of BPs and other therapies could help in initiating and managing treatment more effectively in high-risk patients. In concert, improved understanding of AFF risk factors and pathophysiology could help to identify which patients are at highest risk for AFFs prior to starting therapy. This could ultimately result in maximizing benefits to patients and lowering the "treatment gap" while minimizing AFF risks.
